2025-09-11 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR), incorporating all the provided data points.

## Schrodinger Inc. (SDGR) Analysis

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

### 1. Performance vs. S&P 500 (VOO)

*   **SDGR Cumulative Return:** -53.86%
*   **VOO Cumulative Return:** 39.61%
*   **Absolute Divergence:** -110.1
*   **Relative Divergence:** 0.5 (Near the bottom of its historical range relative to VOO)

**Analysis:**

*   SDGR has significantly underperformed the S&P 500. The negative divergence suggests substantial relative weakness.
*   The relative divergence of 0.5 indicates SDGR's underperformance is near the lowest end of its historical range compared to VOO. It is not that SDGR is 0.5% lower than S&P500 (VOO).  Instead, it indicates that the current relative divergence is near the bottom of its historical range compared to the benchmark index.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2020-2022  | -74.0%  | 68.9% | -64.0%  | 0.0   | 1.3    |
| 2021-2023  | -65.0%  | 68.9% | -75.0%  | -0.0  | 2.5    |
| 2022-2024  | 8.0%   | 72.4% | -22.0%  | -0.0  | 1.3    |
| 2023-2025  | 0.0%   | 74.0% | -46.0%  | -0.0  | 1.3    |

**Analysis:**

*   **CAGR:** Consistently negative CAGR in most periods indicates poor historical growth.
*   **MDD:** High Maximum Drawdown (MDD) values suggest significant price volatility and risk.
*   **Alpha:** Negative Alpha values across all periods imply underperformance relative to the market.
*   **Beta:** Beta values close to 0.0 suggest very low correlation with the S&P 500, indicating the stock's movements are largely independent of the broader market.

### 2. Recent Price Action

*   **Current Price:** $19.46
*   **Last Market Data:** Price: $18.15, Previous Close: $19.46, Change: -6.73%
*   **5-day Moving Average:** 19.258
*   **20-day Moving Average:** 19.493
*   **60-day Moving Average:** 20.4376

**Analysis:**

*   The recent significant price drop (-6.73% from the previous close) signals strong negative momentum.
*   The current price is below the 20-day and 60-day moving averages, suggesting a short-term downtrend.

### 3. Technical Indicators & Market Risk

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk)
*   **RSI:** 50.81 (Neutral)
*   **PPO:** 0.23 (Close to zero, indicating low momentum)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-day Relative Divergence Change:** 0.5 (+): Short-term increase
*   **Expected Return:** -5720.8% (Significantly Negative)

**Analysis:**

*   The MRI indicates a "Low Risk" environment, which might seem contradictory given the other negative indicators. This could be due to the specific calculation methodology of the MRI, or it could suggest that while the stock is risky, the broader market is relatively stable.
*   RSI is neutral, not indicating overbought or oversold conditions.
*   The negative expected return suggests that, based on current trends, the stock is expected to significantly underperform the S&P 500 in the long term.
*   The Hybrid Signal indicates a weak buy signal.

### 4. Recent News & Significant Events

*   **[2025-09-09]** Potential Rally of 40.43% (Zacks): This suggests some analysts see upside potential.
*   **[2025-08-27]** Presentation at Morgan Stanley Conference: Indicates company visibility and engagement with the investment community.
*   **[2025-08-15]** Inducement Grants: These are typically stock options granted to new employees, which can be a positive sign of attracting talent but also dilute existing shareholders.
*   **[2025-08-14]** Discontinuation of SGR-2921 Program: This is a negative sign, suggesting a setback in the company's drug development pipeline.
*   **[2025-08-06]** Q2 Loss, Beats Revenue Estimates (Zacks): Mixed news â€“ the company is still losing money, but revenue is better than expected.

### 4-2. Analyst Opinions

*   **Consensus:** Strong Buy (~1.38)
*   **Target Price:** $28.11 (avg) / $33.00 (high) / $19.00 (low)

**Analysis:**

*   Despite the stock's poor performance, analysts maintain a strong buy rating.
*   The average target price of $28.11 suggests a significant potential upside from the current price.

### 5. Recent Earnings Analysis

| Date       | EPS    | Revenue  |
|------------|--------|----------|
| 2025-08-06 | -0.59  | 0.05 B$  |
| 2025-05-07 | -0.82  | 0.06 B$  |
| 2024-11-12 | -0.52  | 0.04 B$  |
| 2024-07-31 | -0.74  | 0.05 B$  |
| 2025-08-06 | -0.74  | 0.05 B$  |

**Analysis:**

*   The company is consistently reporting losses (negative EPS).
*   Revenue has been relatively stable but not growing significantly.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |
| 2024-06-30 | $0.05B  | 66.20%        |

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | $0.34B  | -12.59%  |
| 2025-03-31 | $0.37B  | -16.01%  |
| 2024-12-31 | $0.42B  | -9.54%   |
| 2024-09-30 | $0.45B  | -8.49%   |
| 2024-06-30 | $0.47B  | -11.40%  |

**Analysis:**

*   Revenue is variable, showing some fluctuations but no clear upward trend.
*   Profit margins are high, indicating that the company is efficient in generating profit from its revenue.
*   Equity is declining, which is a concern.
*   ROE is negative, reflecting the company's inability to generate profits from its equity.

### 7. Overall Assessment

Schrodinger (SDGR) presents a mixed picture:

*   **Negative Factors:** Significant underperformance compared to the S&P 500, negative Alpha, high MDD, consistent losses, declining equity, and a negative expected return. The discontinuation of a drug program is also a setback.
*   **Positive Factors:** Strong Buy analyst consensus with a significant price target upside, high profit margins, and a low Market Risk Indicator (although potentially misleading given the other factors). Recent news also includes a potential rally according to Zacks.

**Conclusion:**

SDGR appears to be a high-risk, high-reward investment. While analysts are optimistic and the company has high profit margins, its historical performance, current financial situation, and recent pipeline setback raise concerns.

**Recommendation:**

Given the data, a cautious approach is warranted. Further due diligence is needed to understand the reasons behind the analyst's optimism and to assess the company's long-term prospects. A small, speculative position might be considered, but only if the investor fully understands and accepts the associated risks.
